Form 8-K Karyopharm Therapeutics For: Apr 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Karyopharm Therapeutics (KPTI) PT Raised to $21 at Wedbush
May 1, 2018 9:59 AM EDTWedbush raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $21.00 (from $19.00) while maintaining a Outperform rating.
Analyst David Nierengarten commented, "Topline results from STORM met our expectations and should be sufficient to support accelerated approval (AA) for selinexor plus dex in... More
